{"groups":[{"description":"Subjects will receive durvalumab and tremelimumab both via intravenous infusion once per day for every 28 day cycles (+ 7 days). Participants will receive tremelimumab for up to 4 cycles (4 doses). Beginning with cycle 5 day 1, subjects will continue to receive durvalumab alone, until clinical or radiological progression.\n\nTremelimumab: Tremelimumab blocks a receptor on immune cells that normally suppresses immune attack.\n\nDurvalumab: Durvalumab is a drug that blocks a protein often produced by cancer cells or surrounding cells to suppress immune cells from attacking cancer cells.","id":"FG000","title":"Tremelimumab + Durvalumab"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"3"}],"type":"Physician Decision"},{"reasons":[{"groupId":"FG000","numSubjects":"14"}],"type":"Progression/Relapse"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"19"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"19"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"recruitmentDetails":"Patients were enrolled from April 2017 to August 2018."}